MiNK Therapeutics, Inc.
NASDAQ Capital MarketTotal Valuation
MiNK Therapeutics, Inc. carries a market capitalization of 63.57M, placing it among publicly traded companies globally. Its enterprise value stands at 36.89M, reflecting the total theoretical takeover cost after accounting for cash holdings and debt obligations.
| Market Cap | 63.57M |
| Enterprise Value | 36.89M |
Share Statistics
MiNK Therapeutics, Inc. currently has 4.97M shares outstanding.
| Shares Outstanding | 4.97M |
| Owned by Insiders (%) | N/A |
| Owned by Institutions (%) | N/A |
Valuation Ratios
| PE Ratio | N/A |
| PS Ratio | N/A |
| PB Ratio | -0.29 |
| P/TBV Ratio | -3.66 |
| P/FCF Ratio | -7.35 |
| P/OCF Ratio | -7.35 |
Financial Position
MiNK Therapeutics, Inc. maintains a current ratio of 1.38, meaning it holds 1.4x the short-term assets needed to cover near-term liabilities.
| Current Ratio | 1.38 |
| Quick Ratio | 1.31 |
| Debt / Equity | N/A |
| Debt / EBITDA | N/A |
| Interest Coverage | N/A |
Financial Efficiency
| Return on Equity (ROE) | N/A |
| Return on Assets (ROA) | -170.30 |
| Return on Invested Capital (ROIC) | N/A |
| Return on Capital Employed (ROCE) | N/A |
| Revenue Per Employee | N/A |
| Employee Count | N/A |
| Inventory Turnover | N/A |
Stock Price Statistics
MiNK Therapeutics, Inc.'s stock has gained approximately 78.96213% over the past 52 weeks. The 50-day moving average sits at 11.22, while the 200-day moving average is 12.35.
| Beta (5Y) | N/A |
| 52-Week Price Change | 78.96213% |
| 50-Day Moving Average | 11.22 |
| 200-Day Moving Average | 12.35 |
| Average Volume (20 Days) | N/A |
Income Statement
EBITDA reached -12.67M, while operating income came in at -12.84M.
| Revenue | N/A |
| Gross Profit | N/A |
| Operating Income | -12.84M |
| Pretax Income | -12.47M |
| Net Income | -12.47M |
| EBITDA | -12.67M |
| EBIT | -12.84M |
| Earnings Per Share (EPS) | -2.83 |
Balance Sheet
Total book value stands at -159.42M, with working capital of 2.74M providing operational flexibility.
| Cash & Cash Equivalents | 9.53M |
| Total Debt | N/A |
| Net Debt | -9.53M |
| Equity (Book Value) | -159.42M |
| Book Value Per Share | -36.17 |
| Working Capital | 2.74M |
Cash Flow
MiNK Therapeutics, Inc. produced -6.32M in operating cash flow over the past twelve months.
| Operating Cash Flow | -6.32M |
| Capital Expenditures | N/A |
| Free Cash Flow | -6.32M |
| FCF Per Share | -1.43 |
Dividends & Yields
| Dividend Per Share | N/A |
| Dividend Yield | N/A |
| Payout Ratio | N/A |
| Shareholder Yield | -27.19 |
| FCF Yield | -13.61 |
Stock Splits
MiNK Therapeutics, Inc.'s most recent stock split took place on January 28, 2025 with a 10:1 split ratio.
| Last Split Date | 1/28/2025 |
| Split Ratio | 10:1 |
Scores
MiNK Therapeutics, Inc. posts an Altman Z-Score of -24.07, below the 3.0 threshold that indicates strong financial health and minimal bankruptcy risk.
| Altman Z-Score | -24.07 |